Literature DB >> 9678832

Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen.

C Ebner1, U Siemann, B Bohle, M Willheim, U Wiedermann, S Schenk, F Klotz, H Ebner, D Kraft, O Scheiner.   

Abstract

BACKGROUND AND
OBJECTIVE: The mechanisms operative in specific immunotherapy (SIT) of Type I allergy are not completely understood. In the present study we evaluated immunological changes during SIT in pollinosis.
METHOD: Eight patients suffering from pollinosis (monosensitized to grass pollen) were treated with conventional SIT. All subjects had IgE specific for Phl p 1, a major allergen of timothy grass. In vitro changes in the immunological reactivity to grass pollen extract and to recombinant Phl p 1 were evaluated. Subjects were examined at three occasions: before, after 3 months and after 1 year of SIT.
RESULTS: Serological analysis revealed a marked increase of grass pollen- and Phl p 1-specific IgG, titres of specific IgE did not change significantly. Lymphoproliferative responses to grass pollen extract and rPhl p 1 were reduced already after 3 months of treatment. Accordingly, the cloning efficiency for Phl p 1-specific T-cell clones (TCC) dropped markedly in all patients. The majority of allergen-specific TCC raised before SIT revealed a TH2-like pattern of cytokine production, TCC established after SIT revealed TH1 characteristics. This shift was due to a decrease in IL-4 rather than an increase in IFN-production by T cells. Investigations of the epitopes recognized by T cells before and after SIT did not reveal the outgrowth of new ('protecting') specificities. We could not observe induction of allergen-specific CD8+ lymphocytes (supressor cells).
CONCLUSION: Our data indicate that -- on the level of TH lymphocytes -- SIT induces tolerance to the allergen and a modulation of the cytokine pattern produced in response to allergen stimulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9678832     DOI: 10.1111/j.1365-2222.1997.tb01252.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  49 in total

Review 1.  Tolerizing allergic responses in the lung.

Authors:  C M Lloyd; J R Murdoch
Journal:  Mucosal Immunol       Date:  2010-05-26       Impact factor: 7.313

2.  High-dose allergen exposure leads to tolerance.

Authors:  Judith A Woodfolk
Journal:  Clin Rev Allergy Immunol       Date:  2005-02       Impact factor: 8.667

Review 3.  [Specific immunotherapy for allergic rhinitis. Current methods and innovative developments].

Authors:  O Pfaar; L Klimek
Journal:  HNO       Date:  2008-08       Impact factor: 1.284

Review 4.  Allergen immunotherapy for allergic respiratory diseases.

Authors:  Antonio Cappella; Stephen R Durham
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 5.  Novel developments in the mechanisms of immune tolerance to allergens.

Authors:  Thomas Eiwegger; Saskia Gruber; Zsolt Szépfalusi; Cezmi A Akdis
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 6.  The identification of potentially pathogenic and therapeutic epitopes from common human allergens.

Authors:  Véronique Schulten; Carla Oseroff; Rafeul Alam; David Broide; Pandurangan Vijayanand; Bjoern Peters; Alessandro Sette
Journal:  Ann Allergy Asthma Immunol       Date:  2012-11-15       Impact factor: 6.347

7.  A new mechanism for inhalational priming: IL-4 bypasses innate immune signals.

Authors:  Anna M Dittrich; Hui-Chen Chen; Lan Xu; Patricia Ranney; Sean Connolly; Timur O Yarovinsky; H Kim Bottomly
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

8.  Tracking antigen-specific T-cells during clinical tolerance induction in humans.

Authors:  Aamir Aslam; Hsien Chan; David A Warrell; Siraj Misbah; Graham S Ogg
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

9.  Immunotherapy with allergen peptides.

Authors:  Mark Larché
Journal:  Allergy Asthma Clin Immunol       Date:  2007-06-15       Impact factor: 3.406

10.  Proteolytically inactive per a 10 allergen of Periplaneta americana modulates Th2 response and enhances IL-10 in mouse model.

Authors:  Deepsikha Srivastava; Amit Kumar Mehta; Naveen Arora; Shailendra Nath Gaur; Bhanu Pratap Singh
Journal:  J Clin Immunol       Date:  2010-01-14       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.